Notably, combined blockade of LAG‐3 and PD‐1 has been shown to restore CD8+ T cell function, paving the way for personalized cellular immunotherapy for DLBCL [21]. The gene discussed is LAG3; the disease is diffuse large B-cell lymphoma.